News Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-14 pm EDT			5-day change	1st Jan Change
0.3819 ^USD	+7.85%		-7.53%	-33.58%

May. 09	Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 10	AQ
Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 09	AQ
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024	May. 02	AQ
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID	Mar. 26	AQ
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 01	AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	Feb. 29	AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones	Feb. 28	AQ
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID	Jan. 22	AQ
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	Jan. 22	CI
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	Jan. 02	CI
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	Jan. 02	AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Virios Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	AQ
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	Nov. 06	AQ
Thinking about buying stock in Aware, Virios Therapeutics, Bit Brother, Confluent, or Blue Star Foods?	Nov. 03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Summary

Filters